0B68 Glass, Jon - Thomas Jefferson University - Thomas Jefferson University
Jon Glass, MD

Jon Glass, MD

Contact Dr.  Glass

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-7000
(215) 503-9170 fax

Most Recent Peer-reviewed Publications

  1. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade 1E6A glioma
  2. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases
  3. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  4. A 60-year-old indian male with altered sensorium and extensive lymphoma of the scalp
  5. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  6. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
  7. Characterization and outcomes of optic nerve gliomas: A population-based analysis
  8. Intravascular lymphoma of the CNS
  9. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
  10. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas
  11. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to l-dopa in the treatment of Parkinson's disease: A randomized, multicenter, open-label, parallel-group study
  12. Central nervous system cancers: Clinical Practice Guidelines in Oncology™
  13. Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: Case report
  14. Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: Case report
  15. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma
  16. Neurologic Complications of Lymphoma and Leukemia
  17. The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
  18. Central nervous system cancers Clinical Practice Guidelines in Oncology
  19. Workshop III: Late motor complications of Parkinson's disease
  20. Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme